Johnson & Johnson has announced its first earnings following its decision to rebrand its pharma segment as Johnson & Johnson Innovative Medicine in September. In the third quarter of 2023, the company reported sales growth of 6.8%, amounting to $21.4 billion. The bestseller for the company was Stelara with sales amounting to $2.864 billion. J&J’s…